Stockwatch: Biotech investing rules, OK?
This article was originally published in Scrip
Life was much simpler for biotech investors in the 1990s. When Human Genome Sciences Inc. (HGSI), completed its IPO in December 1993, the company's price almost doubled after the second day of trading – everyone profited including the bankers, company management and even the company's investors. That pattern mimicked, albeit less spectacularly, the tripling of Genentech's stock price at its IPO back in October 1980, an event which led to the first rule of biotechnology investing: "Buy at IPO".
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.